Cocrystal Pharma, Inc. — Director's Dealing 2014

Mar 17, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIOZONE PHARMACEUTICALS, INC. (BZNE)
CIK: 0001412486
Period of Report: 2014-03-17

Reporting Person: FROST PHILLIP MD ET AL (N/A)
Reporting Person: Frost Gamma Investments Trust (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8640190	Indirect
Common Stock	4545993	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock ()		Indirect
Common Stock Warrants (Right to Buy)	$0.50	2018-04-18	Common Stock (200000)		Indirect

Footnotes

F1: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: These securities are owned directly by The Frost Group, LLC, of which Frost Gamma Investments Trust is a principal member. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: Represents approximately 427,760 shares of Series B preferred stock. The Series B shares automatically convert into 205.08308640 shares of Common Stock when the issuer increases its authorized capital to enable all of the outstanding Series B holders to convert. The Series B shares were issued on January 2, 2014 and do not expire.